PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Unde	er the Paper Cork Reduction A	1995,	no persons are	U.S. Patent and required to respond to a collection of in	Frademark Office: U.S. DEPARTMENT OF COMME Information unless it contains a valid OMB control number	.RCI	
Substitute	e for form 1449A/PTO		_	Complete if Known			
				Application Number	10/532,067		
	INFORMATION DIS	SCLOS	SURE	Filing Date	April 19, 2005		
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ANT	First Named Inventor	Sutter			
			Art Unit	To Be Assigned			
	luca se manu chaote se	noraecai	nul	Examiner Name	To Be Assigned		
Sheet	1	of	2	Attorney Docket Number	GRUE-004		

Number-Kind Code ² (# known)	04-10-2001 05-05-2005	Pasteur Marieux Serums et Vaccins and The University of Hawali Hermann Bujard	
US- US- US- US- US-	05-05-2005	Hermann Bujard	
US- US- US- US-			
US- US- US-			
US-			
US•			
US-			
US-			
	US- US- US-	US- US- US- US-	US- US- US

		FOREIG	N PATENT DO	UMENTS		,
Examiner Initials'	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
8h		WO 02/24224	03-28-2002	Oxxon Pharmaccines Limited		
		DE 196.40.817.A		Hermann Bujard Prof Dr		/
						<u> </u>
		[1

Examiner		harm	Lent	Date Considered	6-20-06
Signature	\sim /	0000	14000	Considered	2

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)
Approved through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

					Complete if Known	
Substitute	for form 1449B/PTO			Application Number	10/532,067	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 2 of 2	Filing Date	April 19, 2005			
				First Named Inventor	Sutter	
				Art Unit	To Be Assigned	
				Examiner Name	To Be Assigned	
Sheet	2	of	2	Attorney Docket Number	GRUE-004	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
Sh		SHUTUNG Y., et al. "Addition of the MSA1 signal and anchor sequences to the malaria merozoite surface antigen 1 C0terminal region enhances immunogenicity when expressed by recombinant vaccinia virus" Vaccine, Butterworth Scientific Guilford, GB, Bd. 15, Nr. 12-13, 1 August 1997, Seiten 1303-1313	
Sh		SCHNEIDER J. et al., "Enhanced Immunogenicity for CD8+ T cell induction and complte protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus ankara" Nature Medicine, Nature Publishing Co. Bd. 4, NR4, April 1998, 397-402	
5h		OBER B et al., "Immunogenicity and safety of defective vaccinia virus Lister: Comparison with modified vaccinia virus Ankara" Journal of Virology, Bd. 76, Nr. 15, August 2002, Seiten, 7713-7723	
Sm		GOOD M.F., et al. "Immune efector mechanisms in malaria" Current Opinion in Immunology, Current Biology Ltd., XX, Bd. 11, Nr. 4, August 1999, Seiten 412-419	
		RAMSHAW, I.A. et al. "The prime-boot strategy: exciting prospects for improved vaccination" Immunology Today, Elsevier Publications, Cambridge, GB, Bd. 21, Nr. 4, April 2000, Seiten 163-165	
			_
		·	
· · · · · · · · · · · · · · · · · · ·			_
Examiner Signature		Sharin Helit Date 6-20-06	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

'Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.